NAFDAC approves Chloroquine production for clinical trial

 

 

The National Agency for Food and Drug Administration and Control (NAFDAC) has announced that it’s approving the production of chloroquine for clinical trials.

The agency’s director-general, Mojisola Adeyeye who made the announcement, urged Nigerians to desist from using chloroquine as an anti-malaria drug because of the resistance that has been proven to develop in the past.

She said:

“In the case of Chloroquine, it has been demonstrated in the literature and with clinical research which is still ongoing, that chloroquine is superior to the placebo.

“NAFDAC is not approving chloroquine as a product that can be used for coronavirus because there is no submission to us for registration. But because it is under clinical trials, NAFDAC approves medicines meant for clinical trials.

“Right now, we have asked one company to make a batch of Chloroquine for the purpose of clinical trial.”

 

Meanwhile the National Centre for Disease Control (NCDC) has warned Nigerians against consuming Chloroquine in the fight against coronavirus.

The warning came prior to the announcement by NAFDAC and on the heels of the U.S president, Donald Trump, announcing that the drug had been approved by the country’s Food and Drug Administration (FDA).

FDA Commissioner, Dr Stephen Hahn, has since denied the approval, reiterating that the effectiveness of the drug is in the process of a clinical trial.

There had been a mad rush for chloroquine in Nigeria pharmacies even after the FDA cleared the air.

The NCDC took to its official Twitter page on Friday to warn Nigerians against self-medication.

The center also advised that they always wait for directives from health workers and authorities.

@WHO has NOT approved the use of chloroquine for #COVID19 management. Scientists are working hard to confirm the safety of several drugs for this disease.

“Please DO NOT engage in self-medication. This will cause harm and can lead to death,”

Share This:

Leave a Reply

%d bloggers like this: